**Table S1: Characteristics of patients starting a second and third TNFi**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | | **Second TNFi**  **N=270** | **Third TNFi**  **N=111** |
| Females (n (%)) | | | 164 (60.7) | 76 (68.5) |
| Age (years; mean (SD)) | | | 47.0 (11.7) | 46.9 (11.2) |
| Disease duration (years; mean (SD)) | | | 15.1 (9.12) | 16.1 (8.2) |
| TNFi (n (%)) | Etanercept Infliximab Adalimumab Golimumab Certolizumab | | 121 (44.8)  34 (12.6)  113 (41.8)  2 (0.7)  0 (0) | 21 (18.9)  31 (27.9)  48 (43.2)  10 (9.0)  1 (0.1) |
| Year of initiation (n) | | 2002  2003  2004  2005  2006  2007  2008  2009  2010  2011  2012  2013 | 0  15  43  38  40  36  31  22  16  7  9  3 | 0  0  11  14  9  11  11  8  17  17  11  2 |

**Figure S1:** Persistence of TNFi by co-medication with MTX

C:\Users\Ivar\Desktop\Karen\MCR\FigureS1_HigRes.tif

Kaplan-Meier plot of time (years) to discontinuation of treatment by co-medication with Methotrexate, statistical comparison by log-rank test. A. Etanercept; p=0.16, B. Infliximab; p=0.75, C. Adalimumab; p=0.92